An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
Status
Conditions
Treatments
Details and patient eligibility
About
The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data.
Full description
The XVIVO registry is an ongoing, observational, multicenter, retrospective review of patients exposed to XPS™ EVLP-treated lungs. The Registry study is aligned and managed by the UNOS and OPTN data collection process. This registry uses quarterly STAR file data requests for the OPTN data managed by UNOS.
The EVLP procedure and transplantation will be performed per XPS™ Instructions for Use and the treating physician's discretion. Post-transplant clinical care will follow the institution's standard-of-care policies.
OPTN updated the data collected since the submission of the protocol therefore the data collection has changed. The following data has updated collection:
- Collects if hospitalized since last follow-up (yes, no), not the number of hospitalizations
- Collects acute rejection episodes (yes treated, yes not treated, no), not the number of episodes
- Collects Karnofsky Score as replacement for Physical and functional capacity
- Employment limitations has been updated to working for income (yes or no)
- No longer collects BOS, XVIVO to request BOS evaluations on subjects with visits prior to June 30, 2020 and any other omissions of end points not available in the data requested via STAR request.
- Collects FEV1 (L) effective June 30, 2020 to calculate CLAD and diagnosis of CLAD, if applicable.
- No longer provides Other, Specify text in STAR request.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
This is an "All Comers Registry" hence will include all patients receiving EVLP lungs.
Trial contacts and locations
Loading...
Central trial contact
Manasa Survi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal